J.P. Morgan analyst Anne Samuel has maintained their bullish stance on IQV stock, giving a Buy rating on February 4.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Anne Samuel’s rating is based on IQVIA Holdings’ strong financial performance, which surpassed both market expectations and its own guidance. The company’s revenue and adjusted EBITDA for the quarter were higher than anticipated, driven by significant growth in the Technology & Analytics Solutions (TAS) segment. Specifically, TAS revenue saw a notable increase, underscoring IQVIA’s ability to navigate the challenging market environment effectively.
Furthermore, IQVIA’s reaffirmation of its 2025 guidance aligns with analyst projections, indicating a steady outlook despite anticipated challenges such as currency fluctuations and a decrease in COVID-related revenues. The company’s strategic focus on maintaining growth in its core segments and leveraging inorganic growth opportunities contributes to its positive future prospects. These factors collectively support the Buy rating as IQVIA continues to demonstrate resilience and adaptability in its business operations.
According to TipRanks, Samuel is a 4-star analyst with an average return of 7.4% and a 44.25% success rate. Samuel covers the Healthcare sector, focusing on stocks such as Progyny, Evolent Health, and Omnicell.